11 December 2024
ANANDA
DEVELOPMENTS PLC
("Ananda"
or the "Company")
Subscription to raise £150,000
Ananda Developments plc (AQSE: ANA),
a company focused on the development of cannabinoid based therapies
for the treatment of a range of complex conditions, is pleased to
announce that it has successfully raised £150,000 from new
shareholders by way of a subscription (the "Subscription") of
42,857,142 new Ordinary Shares (the "Subscription Shares") at a
price of 0.35 pence each (the "Issue Price").
The proceeds of the Subscription will be used
for general working capital and progressing its patent and
regulatory workstreams.
Ananda's CEO,
Melissa Sturgess commented: "We are delighted to welcome more long-term
investors to Ananda. The funds will be put to good use in our
mission to deliver regulated cannabinoid-based medicines to
patients alongside
the over £2 million we successfully raised in
September."
Admission and Total Voting Rights
An application has been made to the
Aquis Stock Exchange for the Subscription Shares to be admitted to
trading on AQSE with effect from 8a.m. on or around 16 December
2024 ("Admission"). The Subscription Shares will rank pari passu
with the existing Ordinary Shares.
Following Admission, the Company
will have 4,299,146,581 Ordinary Shares in issue, each share
carrying the right to one vote. This figure of 4,299,146,581
Ordinary Shares may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change in their
interest in, the share capital of the Company under the FCA's
Disclosure and Transparency Rules.
To stay abreast of the latest
developments at Ananda, we encourage you to follow our social media
channels which are:
·
Investor Hub: investors.anandadevelopments.com
·
Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
·
LinkedIn:
https://www.linkedin.com/company/anadevelopments/
·
Twitter:
https://twitter.com/AnandaPlc
·
Investor Meet Company:
https://www.investormeetcompany.com/ananda-developments-plc/register-investor
-Ends-
The Directors of the Company accept
responsibility for the contents of this
announcement.
|
ANANDA DEVELOPMENTS PLC
|
+44
(0)7463 686 497
|
|
|
ir@anandadevelopments.com
|
|
Chief Executive Officer
|
|
|
Melissa Sturgess
|
|
|
|
|
|
Finance Director
|
|
|
Jeremy
Sturgess-Smith
|
|
|
|
|
|
SP
ANGEL CORPORATE FINANCE LLP
|
+44 (0)20
3470 0470
|
|
|
|
|
Corporate Finance
|
|
|
Richard Morrison
|
|
|
Caroline Rowe
|
|
|
|
|
|
Corporate Broking
|
|
|
Abigail Wayne
|
|
|
Rob Rees
|
|
|
Yellow Jersey PR (media enquiries)
Sarah MacLeod
Charles Goodwin
Zara McKinlay
|
+44 (0)20
3004 9512
ananda@yellowjerseypr.com
|
|
|
|
|
|
|
About Ananda Developments
Ananda is an AQSE-listed
life sciences company focused on the research and
clinical development of CBD-based therapies for a range of complex
inflammatory pain conditions.
For more information, please
visit: https://anandadevelopments.com
Market Abuse Regulation (MAR)
Disclosure
The information contained within
this announcement is deemed by the Company to constitute inside
information. Upon the publication of this announcement via a
Regulatory Information Service, this inside information is now
considered to be in the public domain.
https://investors.anandadevelopments.com/link/WrvwYP
